The document provides a summary of Swadesh Das's professional experience and qualifications. It summarizes that he has over 10 years of experience in research, particularly in microbiology and molecular oncology. He currently works as a research faculty at Virginia Commonwealth University, where he manages research projects and pursues patent applications. He has a PhD in Life Science and expertise in areas like molecular biology, cancer research, and biomarker identification.

1. S W A D E S H D A S , P H D
16007 Soho Turn, Moseley, VA 23120 ÷skdas0272@gmail.com÷804-245-6944
Experienced research professional with 10+ years of experience within high-­‐‑stress environments along with a
keen ability to lead others and perform complex scientific research. Experienced in researching various topics
within microbiology, leading large-­‐‑scale projects, and handling various patent applications. Equipped with a
significant level of communication and interpersonal abilities in addition to a strong educational background
which includes a PhD in Life Science and a Master’s in Agriculture.
K E Y C O M P E T E N C I E S
• Molecular Biology
• Academic Research
• Cell-­‐‑Molecular Biology
• Gene Therapy
• Tumor Cells/Drug Injections
• Student Mentoring
• Cancer Stem Cell Collection
• Clinical Trial Management
• Molecular Drug Development
• Biomarker Identification
• Complex Problem Solving
• Attention to Detail
P R O F E S S I O N A L E X P E R I E N C E
Research Faculty
VIRGINIA COMMONWEALTH UNIVERSITY MAY 2011-­‐‑PRESENT
§ Directly manage a variety of research related functions with a concentration on providing complex
analytical research within the field of molecular oncology and microbiology
§ Perform in-­‐‑depth investigations, develop unique scientific approaches, and facilitate several
administrative tasks such as tracking lab expenses, monitoring inventory, and creating grant applications
§ Play a lead role in several projects which include:
o Development Small Molecule Inhibitors of Cancer Invasion, Attachment, and Metastasis
o Understanding Metastasis Development: In Immunological Perspective
o Identifying Multi-­‐‑Biomarkers Panel for Metastatic Melanoma
o Generation of Metastatic Specific Theranostic Construct
§ Utilize superior research and analytical abilities in order to complete several relevant patent applications
which includes:
o Use of a truncated CCN1 promoter for cancer diagnostics, therapeutics and theranostics;
PCT/US2014/040796; WO/2014/209553
o mda-­‐‑9/syntenin promoter to image and treat metastatic cancer cells. PCT/US2014/040898;
WO/2014/197586
o Tripartite cancer theranostic nucleic acid constructs; PCT/US2014/040912; WO/2014/197598
o Diagnostic and Prognostic Markers for Metastasis, United States Patent Application 20130338033”
Postdoctoral Fellow
VIRGINIA COMMONWEALTH UNIVERSITY MARCH 2008-­‐‑MAY 2011
KOBE UNIVERSITY JANUARY 2007-­‐‑MARCH 2008
TOKYO UNIVERSITY OF AGRICULTURE APRIL 2006-­‐‑DECEMBER 2006
§ Coordinated several operational functions within an educational environment with a focus on completing
complex microbiology related research
Additional Experience Includes: Research Officer, International Center for Diarroheal Research of Bangladesh
E D U C A T I O N
PHD, LIFE SCIENCE, KOBE UNIVERSITY, KOBE, JAPAN
MASTER IN AGRICULTURE, KOBE UNIVERSITY, KOBE, JAPAN
MASTER OF SCIENCE, MICROBIOLOGY, UNIVERSITY OF DHAKA, DHAKA, BANGLADESH
BACHELOR OF SCIENCE, MICROBIOLOGY, UNIVERSITY OF DHAKA, DHAKA, BANGLADESH

2. S W A D E S H D A S
16007 Soho Turn, Moseley, VA 23120 ÷skdas0272@gmail.com÷804-245-6944
S E L E C T P U B L I C A T I O N S
§ Menezes ME, Shen XN, Das SK, Emdad L, Guo C, Yuan F, Li YJ, Archer MC, Zacksenhaus E, Windle JJ,
Subler MA, Ben-­‐‑David Y, Sarkar D, Wang XY, Fisher PB. MDA-­‐‑7/IL-­‐‑24 functions as a tumor suppressor
gene in vivo in transgenic mouse models of breast cancer. Oncotarget. 2015 Oct 12.
§ Bacolod MD, Das SK, Sokhi UK, Bradley S, Fenstermacher DA, Pellecchia M, Emdad L, Sarkar D, Fisher
PB. Examination of Epigenetic and other Molecular Factors Associated with mda-­‐‑9/Syntenin
Dysregulation in Cancer Through Integrated Analyses of Public Genomic Datasets. Adv Cancer Res.
2015;127:49-­‐‑121.
§ Talukdar S, Emdad L, Das SK, Sarkar D, Fisher PB. Noninvasive approaches for detecting and monitoring
bladder cancer. Expert Opinion On Investigational Drugs. 2015 Mar;15(3):283-­‐‑94.
§ Das SK, Menezes ME, Bhatia S, Wang X-­‐‑Y, Emdad L, Sarkar D, Fisher PB. Gene therapies for cancer:
strategies, challenges and successes. 2014. Journal of Cellular Physiology 2015 Feb;230(2):259-­‐‑71.
§ Das SK, Sarkar S, Dash R, Dent P, Wang X-­‐‑Y, Sarkar D and Fisher PB. (2012). Cancer Terminator Viruses
and Approaches for Enhancing Therapeutic Outcomes. Advances in Cancer Research 115:1-­‐‑38.
§ Das SK, Bhutia SK, Azab B, Kegelman TP, Peachy L, Santhekadur PK, Dasgupta S, Dash R, Dent P, Grant
S, Emdad L, Pellecchia M, Sarkar D, and Fisher PB. MDA-­‐‑9/Syntenin and IGFBP-­‐‑2 Promote Angiogenesis
in Human Melanoma Cancer Research, 2013, 73(2):844-­‐‑54.
§ Das SK, Bhutia SK, Azab B, Su Zz, Boukerche H, Chatterjee D, Sarkar D, Fisher PB. Raf kinase inhibitor
RKIP inhibits MDA-­‐‑9/syntenin-­‐‑mediated metastasis in melanoma Cancer Research, 2012, 72(23):6217-­‐‑26.
§ Das SK, Sokhi UK, Bhutia SK, Azab B, Su ZZ, Sarkar D, Fisher PB. Selective degradation of microRNA-­‐‑
221 by human polynucleotide phosphorylase (hPNPaseold-­‐‑35) mediates IFN-­‐‑β-­‐‑induced growth inhibition
in human melanoma cells. Proceedings of National Academy of Science, USA 2010, 107:11948-­‐‑11953.
§ Das SK, Rendong R, Hashimoto T, Knazawa K. Fucoxanthin Induces Apoptosis in Osteoclast-­‐‑like Cells
Differentiated from RAW264.7 Cells. J Agriculture and Food Chemistry 2010, 26: 6090-­‐‑6095.
§ Qadri F, Das SK, Faruque AS, Fuchs GJ, Albert MJ, Sack RB, Svennerholm AM. Prevalence of toxin types
and colonization factors in enterotoxigenic Escherichia coli isolated during a 2-­‐‑year period from diarrheal
patients in Bangladesh. Journal of Clinical Microbiology 2000, 38: 27-­‐‑31.